a Department of Medical Genetics , National and Kapodistrian University of Athens, St. Sophia's Children's Hospital , Athens , Greece.
b Department of Clinical Genetics , Laboratory for Diagnostic Genome Analysis (LDGA) , Leiden , The Netherlands.
Expert Rev Mol Diagn. 2017 Mar;17(3):281-291. doi: 10.1080/14737159.2017.1285701. Epub 2017 Feb 2.
Hemoglobinopathies constitute the most common severe monogenic disorders worldwide, with an increasing global burden each year. The benefit of applying programmes for preconception carrier screening, with the option of prenatal diagnosis, to minimize the incidence of new cases is recognized in many countries. Areas covered: The challenges associated with identifying carrier couples using hematology-based screening, along with DNA diagnosis and prenatal diagnosis were addressed, based on a literature search and the authors expertise. Expert commentary: The hemoglobinopathies are extremely heterogeneous at the haematological, molecular and clinical level, requiring appropriately equipped and staffed laboratories with experience to support comprehensive screening and diagnosis. However complete services with adequate infrastructure to address the associated technical challenges do not exist widely, especially in low-income countries that, coincidentally, are often those with the highest frequency of hemoglobinopathies in their population. Additionally, overcoming limited public awareness, education and absence of systematic dissemination of information also constitutes a challenge. This article aims to highlight these challenges and to evaluate potential future developments that may address at least some of them, focusing mainly on the technical challenges related to molecular diagnostics.
血红蛋白病是全球最常见的严重单基因疾病,每年的全球负担都在增加。许多国家都认识到,通过开展孕前携带者筛查计划并提供产前诊断,以尽量减少新发病例的益处。
根据文献检索和作者的专业知识,探讨了基于血液学筛查、DNA 诊断和产前诊断来确定携带者夫妇所面临的挑战。
血红蛋白病在血液学、分子和临床水平上具有极高的异质性,需要配备有经验的实验室和人员来支持全面的筛查和诊断。然而,能够完全解决相关技术挑战的广泛存在的服务,尤其是在那些血红蛋白病发病率最高的低收入国家中并不常见。此外,克服公众意识有限、教育水平低和缺乏系统信息传播也是一个挑战。本文旨在强调这些挑战,并评估可能解决其中一些挑战的未来发展,主要侧重于与分子诊断相关的技术挑战。